science pharmaceutical expo biotech jobs
Originally published online as doi:10.1189/jlb.0207128 on June 26, 2007

Published online before print June 26, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0207128v1
82/3/479    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, S.
Right arrow Articles by Szabo, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, S.
Right arrow Articles by Szabo, G.
(Journal of Leukocyte Biology. 2007;82:479-487.)
© 2007 by Society for Leukocyte Biology

Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins

Serena Chang, Angela Dolganiuc and Gyongyi Szabo1

Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA

1 Correspondence: Department of Medicine, University of Massachusetts Medical School, LRB 215, 364 Plantation Street, Worcester, MA 01605-2324, USA. E-mail: gyongyi.szabo{at}umassmed.edu

ABSTRACT

Hepatitis C virus (HCV) is a leading cause of end-stage liver disease through sustained inflammation of the liver produced by the host’s immune system. The mechanism for HCV evasion or activation of the immune system is not clear. TLRs are cellular activators of the innate immune system. We recently reported that TLR2-mediated innate immune signaling pathways are activated by HCV core and NS3 proteins. TLR2 activation requires homo- or heterodimerization with TLR1 or TLR6. Here, we aimed to determine whether TLR2 coreceptors participated in cellular activation by HCV core or NS3 proteins. By designing small interfering RNAs targeted to TLR2, TLR1, and TLR6, we showed that knockdown of each of these receptors impairs pro- and anti-inflammatory cytokine activation by TLR-specific ligands as well as by HCV core and NS3 proteins in human embryonic kidney-TLR2 cells and in primary human macrophages. We found that HCV core and NS3 proteins induced TNF-{alpha} and IL-10 production in human monocyte-derived macrophages, which was impaired by TLR2, TLR1, and TLR6 knockdown. Contrary to human data, results from TLR2, TLR1, or TLR6 knockout mice indicated that the absence of TLR2 and its coreceptor TLR6, but not TLR1, prevented the HCV core and NS3 protein-induced peritoneal macrophage activation. In conclusion, TLR2 may use TLR1 and TLR6 coreceptors for HCV core- and NS3-mediated activation of macrophages and innate immunity in humans. These results imply that multiple pattern recognition receptors could participate in cellular activation by HCV proteins.

Key Words: TNF-{alpha} • IL-10 • IL-6 • siRNA




This article has been cited by other articles:


Home page
GutHome page
A Mencin, J Kluwe, and R F Schwabe
Toll-like receptors as targets in chronic liver diseases
Gut, May 1, 2009; 58(5): 704 - 720.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
V. A. Dennis, S. Dixit, S. M. O'Brien, X. Alvarez, B. Pahar, and M. T. Philipp
Live Borrelia burgdorferi Spirochetes Elicit Inflammatory Mediators from Human Monocytes via the Toll-Like Receptor Signaling Pathway
Infect. Immun., March 1, 2009; 77(3): 1238 - 1245.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. R. Murawski, G. N. Bowen, A. M. Cerny, L. J. Anderson, L. M. Haynes, R. A. Tripp, E. A. Kurt-Jones, and R. W. Finberg
Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2
J. Virol., February 1, 2009; 83(3): 1492 - 1500.
[Abstract] [Full Text] [PDF]


Home page
JPEN J Parenter Enteral NutrHome page
S. Dasarathy
Inflammation and Liver
JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 660 - 666.
[Full Text] [PDF]